Detalles de la búsqueda
1.
Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.
Lancet
; 398(10313): 1811-1824, 2021 11 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-34672967
2.
Transitioning to active-controlled trials to evaluate cardiovascular safety and efficacy of medications for type 2 diabetes.
Cardiovasc Diabetol
; 21(1): 163, 2022 08 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-36002856
3.
Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus: Lessons Learned and Future Directions.
Circulation
; 141(10): 843-862, 2020 03 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31992065
4.
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Lancet
; 394(10193): 121-130, 2019 07 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31189511
5.
Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease.
N Engl J Med
; 376(20): 1933-1942, 2017 05 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-28514624
6.
The dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes.
Diabetes Obes Metab
; 22(12): 2451-2459, 2020 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33462955
7.
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States.
Diabetes Obes Metab
; 21(6): 1299-1304, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30714309
8.
Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.
Circ J
; 81(11): 1686-1692, 2017 Oct 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28652529
9.
Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.
Circ J
; 82(1): 183-191, 2017 12 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-28768921
10.
Navigating the Future of Cardiovascular Drug Development-Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference.
Cardiovasc Drugs Ther
; 31(4): 445-458, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28735360
11.
Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial.
Am Heart J
; 170(6): 1061-9, 2015 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-26678626
12.
Prasugrel versus clopidogrel in patients with acute coronary syndromes.
N Engl J Med
; 357(20): 2001-15, 2007 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-17982182
13.
Effect of C-Reactive Protein on Lipoprotein(a)-Associated Cardiovascular Risk in Optimally Treated Patients With High-Risk Vascular Disease: A Prespecified Secondary Analysis of the ACCELERATE Trial.
JAMA Cardiol
; 5(10): 1136-1143, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32639518
14.
Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial.
BMJ Open Diabetes Res Care
; 8(1)2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32179516
15.
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy.
J Am Heart Assoc
; 9(1): e014328, 2020 01 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-31852422
16.
Designing, Conducting, Monitoring, and Analyzing Data from Pragmatic Randomized Clinical Trials: Proceedings from a Multi-stakeholder Think Tank Meeting.
Ther Innov Regul Sci
; 54(6): 1477-1488, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32514736
17.
Population pharmacokinetic analyses to evaluate the influence of intrinsic and extrinsic factors on exposure of prasugrel active metabolite in TRITON-TIMI 38.
J Clin Pharmacol
; 49(8): 984-98, 2009 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-19546250
18.
Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial.
Diab Vasc Dis Res
; 16(2): 171-177, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31014095
19.
Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High-Risk Vascular Disease: Insights From the ACCELERATE Trial.
J Am Heart Assoc
; 8(23): e013790, 2019 12 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31752637
20.
ADCY9 Genetic Variants and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease: A Nested Case-Control Study.
JAMA Cardiol
; 3(5): 401-408, 2018 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29525816